Charlotte's Milestone Pharmaceuticals advancing heart drug |

Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is back on track with a potential drug to treat rapid heart rates in certain cardiovascular disorders.The company in late March re-submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of etripamil for the management of paroxysmal supraventricular tachycardia (PSVT), a type of arrhythmia or abnormal heart rhythm. 

Related Keywords

Shanghai , China , Montreal , Quebec , Canada , United States , Raleigh , North Carolina , Charlotte , Denmark , Duke University , Ji Xing , Jilin , Americans , Canadian , Danish , Joseph Oliveto , Corie Curtis , Ji Xing Pharmaceuticals , Drug Administration , Research Triangle , Research Triangle Region , Carolina Biotechnology Center , Greater Charlotte Advisory Committee , Biotech Center , Ncbiotech Greater Charlotte Office , Duke University School Of Medicine , Nasdaq , Milestone Pharmaceuticals , Lundbeck , New Drug Application , North Carolina Biotechnology , Duke University School , Charlotte Based Chelsea Therapeutics , Queen City , Greater Charlotte , Pappas Ventures ,